← All tickers

Is ABCL Worth Buying in 2026?

AbCellera Biologics Inc. Common Shares

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-07

Here’s whether AbCellera Biologics Inc. Common Shares (ABCL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+11.90% over 10 days); strong 1-year return of +137.1%; 3-month momentum positive (+59.7%). Currently 17.2% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

ABCL is in a confirmed uptrend, trading above both its 50-day ($4.43) and 200-day ($4.21) moving averages. An RSI of 66.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +137.1% compares to +24.4% for SPY (beat the market by 112.8%).

$10,000 invested 1 year ago → $23,713 today
vs. S&P 500 (SPY) — same period beat market by 112.8%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($4.21)
✓Above 50-day MA ($4.43)
✓RSI(14) neutral zone (30–70) — currently 66.2
✓Positive return (+137.1%)
!Within 10% of period high (−17.2%)
Period Range $5.62
$2.33 $6.79
RSI (14) 66.2
0 · OversoldOverbought · 100

Key Metrics

Price$5.62
Period Return+137.1%
Period High$6.79
Period Low$2.33
Drawdown−17.2%
MA-50$4.43
MA-200$4.21
RSI (14)66.2
Avg Volume (30d)9.6M
vs. SPYbeat by 112.8%
Return Rank#150 of 1245

Trade ABCL

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers